AMZN

207.08

-1.46%↓

TSLA

382.42

+0.43%↑

HD

330.59

-0.06%↓

TM

209.02

-0.58%↓

MCD

307.93

-0.08%↓

AMZN

207.08

-1.46%↓

TSLA

382.42

+0.43%↑

HD

330.59

-0.06%↓

TM

209.02

-0.58%↓

MCD

307.93

-0.08%↓

AMZN

207.08

-1.46%↓

TSLA

382.42

+0.43%↑

HD

330.59

-0.06%↓

TM

209.02

-0.58%↓

MCD

307.93

-0.08%↓

AMZN

207.08

-1.46%↓

TSLA

382.42

+0.43%↑

HD

330.59

-0.06%↓

TM

209.02

-0.58%↓

MCD

307.93

-0.08%↓

AMZN

207.08

-1.46%↓

TSLA

382.42

+0.43%↑

HD

330.59

-0.06%↓

TM

209.02

-0.58%↓

MCD

307.93

-0.08%↓

Search

MarineMax Inc

Open

SectorConsumenten cyclisch

26.58 0.38

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

25.53

Max

26.7

Belangrijke statistieken

By Trading Economics

Inkomsten

23M

-8.1M

Verkoop

-47M

505M

K/W

Sectorgemiddelde

10.906

33.36

EPS

-0.21

Winstmarge

-1.602

Werknemers

3,385

EBITDA

-9.3M

18M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+15.93% upside

Dividenden

By Dow Jones

Volgende Winsten

23 apr 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-37M

574M

Vorige openingsprijs

26.2

Vorige sluitingsprijs

26.58

Nieuwssentiment

By Acuity

20%

80%

33 / 338 Rangschikking in Consumer cyclical

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

MarineMax Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 mrt 2026, 23:47 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mrt 2026, 22:55 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mrt 2026, 21:51 UTC

Acquisities, Fusies, Overnames

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mrt 2026, 23:59 UTC

Marktinformatie

Global Equities Roundup: Market Talk

23 mrt 2026, 23:59 UTC

Marktinformatie

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mrt 2026, 23:50 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mrt 2026, 23:37 UTC

Marktinformatie

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mrt 2026, 22:42 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Global Equities Roundup: Market Talk

23 mrt 2026, 22:42 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mrt 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mrt 2026, 22:23 UTC

Marktinformatie

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mrt 2026, 22:22 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mrt 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mrt 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mrt 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mrt 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mrt 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mrt 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mrt 2026, 22:18 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mrt 2026, 22:15 UTC

Acquisities, Fusies, Overnames

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mrt 2026, 22:08 UTC

Marktinformatie

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mrt 2026, 21:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

23 mrt 2026, 21:42 UTC

Marktinformatie

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mrt 2026, 21:10 UTC

Belangrijke Nieuwsgebeurtenissen

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mrt 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

23 mrt 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

23 mrt 2026, 20:50 UTC

Marktinformatie
Winsten
Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

Peer Vergelijking

Prijswijziging

MarineMax Inc Prognose

Koersdoel

By TipRanks

15.93% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 30.5 USD  15.93%

Hoogste 32 USD

Laagste 29 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor MarineMax Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Technische score

By Trading Central

20.955 / 22.13Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

33 / 338 Rangschikking in Consumenten cyclisch

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over MarineMax Inc

MarineMax, Inc. operates as a recreational boat and yacht retailer and superyacht services company in the United States. It operates through two segments, Retail Operations and Product Manufacturing. The company sells new and used recreational boats, including pleasure and fishing boats, mega-yachts, yachts, sport cruisers, motor yachts, e-power yachts, pontoon boats, ski boats, jet boats, and other recreational boats. It also offers marine parts and accessories comprising marine electronics; dock and anchoring products that include boat fenders, lines, and anchors; boat covers; trailer parts; water sport accessories, which comprise tubes, lines, wakeboards, and skis; engine parts; oils; lubricants; steering and control systems; corrosion control products and service products; high-performance accessories, including propellers and instruments; and a line of boating accessories, such as life jackets, inflatables, and water sports equipment. In addition, the company provides novelty items, such as shirts, caps, and license plates; marine engines and equipment; maintenance, repair, and slip and storage services; and boat or yacht brokerage services, as well as yacht charters and power catamarans. Further, it offers new or used boat finance services; arranges insurance coverage, including boat property, disability, undercoating, gel sealant, fabric protection, trailer tire and wheel protection, and casualty insurance coverage; and manufactures and sells sport yachts and yachts. Additionally, the company operates MarineMax vacations in Tortola and British Virgin Islands. It also markets and sells its products through offsite locations and print catalog. MarineMax, Inc. was incorporated in 1998 and is based in Oldsmar, Florida.
help-icon Live chat